Anti hyperlipidemia drugs and flight
|
K Ghazizadeh * |
|
|
Abstract: (14423 Views) |
Nowadays one of the most important reasons of death is
Atherosclerosis. Drug therapy in hyperlipidemia prevents from
Atherosclerosis side effects (such as cardiac attack, peripheral
arterial diseases & strokes) and reduces mortality in patients with
past history of hyperlipidemia and cardiovascular diseases.
FAA (In civil part) permits aircrew to use some of these medications
if there is not any side effects as Health Canadian Air Force
Guidelines (In military part), pharmalogical treatment for
hyperlipidemia should be initiated only after a reasonable trial of diet
and life-style modification and if required treatment with an HMGCoA
reductase inhibitor is recommended.
In hypertrigliceridemia the use of a fibrate maybe indicated.
Aircrew should be grounded for the first two weeks during the
initiation of drug therapy for hyperlipidemia and require bimonthly
monitoring of lipid & transaminase levels during the first six months
of treatment and can use these drugs during flight if there are not
any side effects. |
|
Keywords: Atherosclerosis, Hyperlipidemia, Flight |
|
Full-Text [PDF 243 kb]
(2813 Downloads)
|
Type of Study: Original |
Received: 2012/03/8 | Accepted: 2014/06/3 | Published: 2014/06/3
|
|
|
|